摘要
回顾了2024年ASCO-GU会议上关于尿路上皮癌的最新研究,主要讨论了淋巴结阳性肌层浸润性膀胱癌(N_(+)MIBC)的治疗策略和MIBC术后的辅助治疗。N_(+)MIBC患者面临较高的复发风险,需要综合治疗策略。新辅助化疗和免疫治疗的联合方案显示出显著的疗效,此外,保留膀胱治疗和免疫维持治疗在延长无病生存期方面展现出潜力。AMBASSADOR和CheckMate-274研究的结果显示,高危MIBC术后免疫辅助治疗有利于延缓疾病复发。这些进展为高危MIBC患者的治疗提供了新的希望,并可能改善患者的预后。
This article reviews the latest research on urothelial carcinoma presented at the 2024 ASCO-CU conference,focusing primarily on the treatment strategies for node-positive muscle-invasive bladder cancer(N_(+)MIBC)and adjuvant therapy post-surgery for muscle-invasive bladder cancer.Patients with N_(+)MIBC are at a higher risk of recurrence and require a comprehensive treatment approach.The combination of neoadjuvant chemotherapy and immunotherapy has demonstrated significant efficacy.Additionally,bladdersparing treatment and immuno-maintenance therapy show promise in improving disease-free survival.The results from the AMBASSADOR and CheckMate-274 studies indicate that postoperative immuno-adjuvant therapy for high-risk MIBC is beneficial in delaying disease recurrence.These advancements offer new hope for the treatment of patients with high-risk MIBC and may potentially improve patient outcomes.
作者
鲍一歌
虞巍
何志嵩
魏强
Bao Yige;Yu Wei;He Zhisong;Wei Qiang(Department of Urology and Institute of Urology,West China Hospital,Sichuan University,Chengdu 610041 China;Department of Urology,Peking University First Hospital,Beijing 100034,China)
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2024年第4期254-257,共4页
Chinese Journal of Urology
